Search

Your search keyword '"Döhner, Konstanze"' showing total 1,703 results

Search Constraints

Start Over You searched for: Author "Döhner, Konstanze" Remove constraint Author: "Döhner, Konstanze" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
1,703 results on '"Döhner, Konstanze"'

Search Results

1. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

2. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

3. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

4. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts

5. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients

7. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

9. Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin

10. In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts

11. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

12. AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology

13. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

14. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

16. Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients

17. Netboost: Boosting-supported network analysis improves high-dimensional omics prediction in acute myeloid leukemia and Huntington's disease

18. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial

19. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial

20. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

21. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications

23. Unified classification and risk-stratification in Acute Myeloid Leukemia

25. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal

26. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

27. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

28. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations

30. Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

31. Germline variants drive myelodysplastic syndrome in young adults

34. Genomic characterization of AML with aberrations of chromosome 7:a multinational cohort of 519 patients

36. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial

37. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication

38. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

40. TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition

42. Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

43. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells

45. Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)

47. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

48. The ParaHox gene Cdx4 induces acute erythroid leukemia in mice

49. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

50. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

Catalog

Books, media, physical & digital resources